Novel immunotherapies

Cancer Journal

Volumn 15, Issue 6, 2009, Pages 502-510

  Yi, Qing ^a  

^a Center for Cancer Immunology Research   (United States)

Author keywords

Antibodies; Immunotherapy; Multiple myeloma; T cells; Tumor antigens

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BHQ 880; CANCER VACCINE; CD40 LIGAND MONOCLONAL ANTIBODY; CS1 MONOCLONAL ANTIBODY; DENDRITIC CELL VACCINE; DICKKOPF 1 PROTEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HCD 122; IDIOTYPE PROTEIN; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY; SGN 40; SPERM PROTEIN 17; STEROID; TUMOR ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN SPECIFICITY; APOPTOSIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL STUDY; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DONOR LYMPHOCYTE INFUSION; DRUG INHIBITION; ENZYME LINKED IMMUNOSPOT ASSAY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR CELL; TUMOR IMMUNITY;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BETA 2-MICROGLOBULIN; CANCER VACCINES; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MULTIPLE MYELOMA; RECEPTORS, IMMUNOLOGIC; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS; VACCINES, DNA;

EID: 75149171977     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181c51f0d     Document Type: Review

References (131)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.
2. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.
3. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008-4010.
4. Yi Q. Immunotherapy in multiple myeloma: current strategies and future prospects. Expert Rev Vaccines. 2003;2:391-398.
5. Yi Q. Vaccines for Hematological Malignancies. Totowa, NJ: Humana Press; 2004.
6. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87:1196-1198.
7. Verdonck LF, Lokhorst HM, Dekker AW, et al. Graft-versus-myeloma effect in two cases. Lancet. 1996;347:800-801.
8. Yi Q. Immunoregulatory Mechanisms and Immunotherapy. London: Martin Dunitz; 2002.
9. Sze DM, Giesajtis G, Brown RD, et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(-)CD57(-)CD28(-) compartment. Blood. 2001;98:2817-2827.
10. Alexanian R, Dimopoulos MA, Hester J, et al. Early myeloablative therapy for multiple myeloma. Blood. 1994;84:4278-4282. (Pubitemid 24371933)
11. San Miguel JF, Garcia-Sanz R, Gonzalez M, et al. Immunophenotype and DNA cell content in multiple myeloma. Baillieres Clin Haematol. 1995;8: 735-759.
12. San Miguel JF, Almeida J, Mateo G, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood. 2002;99:1853-1856.
13. Wearne AJ, Joshua DE, Young GA, et al. Multiple myeloma: light chain isotype suppression-a marker of stable disease at presentation. Eur J Haematol. 1987;38:43-49.
14. Duperray C, Klein B, Durie BG, et al. Phenotypic analysis of human myeloma cell lines. Blood. 1989;73:566-572.
15. Yi Q, Dabadghao S, Osterborg A, et al. Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells. Blood. 1997;90: 1960-1967.
16. Szea DM, Brown RD, Yang S, et al. Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leuk Lymphoma. 2003;44:1557-1568.
17. Leo R, Boeker M, Peest D, et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol. 1992;64:132-139.
18. Barker HF, Hamilton MS, Ball J, et al. Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells. Br J Haematol. 1992;81:331-335.
19. Pellat-Deceunynck C, Bataille R, Robillard N, et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood. 1994;84:2597-2603.
20. Westendorf JJ, Ahmann GJ, Armitage RJ, et al. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol. 1994;152:117-128.
21. Hata H, Matsuzaki H, Takeya M, et al. Fas/Apo-1 (CD95)-mediated and CD95-independent apoptosis of malignant plasma cells. Leuk Lymphoma. 1996;24:35-42.
22. Silvestris F, Cafforio P, Tucci M, et al. Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood. 2002;99: 1305-1313. (Pubitemid 34547085)
23. Pope B, Brown RD, Gibson J, et al. B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy. Blood. 2000;96:1274-1279.
24. Sirisinha S, Eisen HN. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci USA. 1971;68:3130-3135.
25. Stevenson FK, Gordon J. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation. J Immunol. 1983;130: 970-973.
26. Kaminski MS, Kitamura K, Maloney DG, et al. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol. 1987;138:1289-1296.
27. Campbell MJ, Esserman L, Byars NE, et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol. 1990;145:1029-1036.
28. King CA, Spellerberg MB, Zhu D, et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med. 1998;4:1281-1286.
29. Holm G, Bergenbrant S, Lefvert AK, et al. Anti-idiotypic immunity as a potential regulator in myeloma and related diseases. Ann NY Acad Sci. 1991;636:178-183.
30. Yi Q, Bergenbrant S, Osterborg A, et al. T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies. Scand J Immunol. 1993;38:529-534.
31. Yi Q, Osterborg A, Bergenbrant S, et al. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood. 1995;86:3043-3049.
32. Osterborg A, Yi Q, Bergenbrant S, Holm G, et al. Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. Br J Haematol. 1995;89:110-116.
33. Wen YJ, Ling M, Bailey-Wood R, et al. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res. 1998;4:957-962.
34. Fagerberg J, Yi Q, Gigliotti D, et al. T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Int J Cancer. 1999;80:671-680.
35. Hansson L, Rabbani H, Fagerberg J, et al. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood. 2003;101:4930-4936.
36. Yi Q, Eriksson I, He W, et al. Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets. Br J Haematol. 1997;96:338-345.
37. Dabadghao S, Bergenbrant S, Anton D, et al. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br J Haematol. 1998;100:647-654.
38. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today. 1991;12:256-257.
39. Romagnani S. Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol. 1992;98:279-285.
40. Walchner M, Wick M. Elevation of CD8+ CD11b+ Leu-8+ T cells is associated with the humoral immunodeficiency in myeloma patients. Clin Exp Immunol. 1997;109:310-316.
41. Salgame P, Abrams JS, Clayberger C, et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science. 1991; 254:279-282.
42. Wen YJ, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood. 2001;97:1750-1755.
43. Wen YJ, Min R, Tricot G, et al. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood. 2002;99:3280-3285.
44. Gong J, Koido S, Chen D, et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood. 2002;99:2512-2517.
45. Liu Y, Zhang W, Chan T, et al. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk Res. 2002;26:757-763.
46. Raje N, Hideshima T, Davies FE, et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004;125:343-352.
47. Milazzo C, Reichardt VL, Muller MR, et al. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood. 2003;101:977-982.
48. Mao B, Wu W, Li Y, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature. 2001;411:321-325.
49. Zorn AM. Wnt signalling: antagonistic Dickkopfs. Curr Biol. 2001;11: R592-R595.
50. Glinka A, Wu W, Delius H, et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 1998;391:357-362.
51. Gregory CA, Singh H, Perry AS, et al. The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem. 2003;278:28067-28078.
52. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483-2494.
53. Yaccoby S, Ling W, Zhan F, et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109:2106-2111.
54. Heath DJ, Chantry AD, Buckle CH, et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res. 2009;24: 425-436.
55. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114:371-379.
56. van Baren N, Brasseur F, Godelaine D, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood. 1999;94:1156-1164.
57. Pellat-Deceunynck C, Mellerin MP, Labarriere N, et al. The cancer germ- line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol. 2000;30:803-809.
58. Dhodapkar MV, Osman K, Teruya-Feldstein J, et al. Expression of cancer/ testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NYESO- 1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun. 2003;3:9.
59. Gupta SK, Shaughnessy J, Droojenbroeck JV, et al. NY-ESO-1 RNA and protein expression in multiple myeloma is highest in aggressive myeloma and is correlated with chromosomal abnormalities. Blood. 2002;100:401a.
60. Gupta SK, Pei L, Droojenbroeck JV, et al. Intra- and intertumoral variation in the expression of cancer testis antigens, MAGE-3 and NY-ESO-1 in multiple myeloma. Blood. 2002;100:603a.
61. Szmania SM, Bennett G, Batchu RB, et al. Dendritic cells pulsed with NY-ESO-1 and MAGE-3 peptide stimulate myeloma cytotoxic T lymphocytes. Blood. 2002;100:399a.
62. van Rhee F, Szmania SM, Zhan F, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005;105:3939-3944.
63. Treon SP, Mollick JA, Urashima M, et al. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood. 1999;93:1287-1298.
64. Akagi J, Nakagawa K, Egami H, et al. Induction of HLA-unrestricted and HLA-class-II-restricted cytotoxic T lymphocytes against MUC-1 from patients with colorectal carcinomas using recombinant MUC-1 vaccinia virus. Cancer Immunol Immunother. 1998;47:21-31.
65. Moore A, Medarova Z, Potthast A, et al. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res. 2004;64:1821-1827.
66. Lim SH, Wang Z, Chiriva-Internati M, et al. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood. 2001;97:1508-1510.
67. Lim SH, Chiriva-Internati M, Wang Z, et al. Sperm protein 17 (Sp17) as a tumor vaccine for multiple myeloma. Blood. 2002;100:673a.
68. Ohtomo T, Sugamata Y, Ozaki Y, et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun. 1999;258:583-591.
69. Ono K, Ohtomo T, Yoshida K, et al. The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity. Mol Immunol. 1999;36:387-395.
70. Treon SP, Raje N, Anderson KC. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol. 2000;27:598-613.
71. Noto H, Takahashi T, Makiguchi Y, et al. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Intern Immunol. 1997;9: 791-798.
72. Chiriva-Internati M, Wang Z, Salati E, et al. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood. 2002;100: 961-965.
73. Lacy HM, Sanderson RD. Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion. Blood. 2001;98:2160-2165.
74. Bergenbrant S, Yi Q, Osterborg A, et al. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol. 1996;92:840-846.
75. Osterborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood. 1998;91:2459-2466.
76. Hansson L, Abdalla AO, Moshfegh A, et al. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res. 2007;13:1503-1510.
77. Massaia M, Borrione P, Battaglio S, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood. 1999;94:673-683.
78. Coscia M, Mariani S, Battaglio S, et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia. 2004;18:139-145.
79. Dabadghao S, Bergenbrant S, Anton D, et al. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br J Haematol. 1998;100:647-654.
80. Butch AW, Kelly KA, Munshi NC. Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein. Exp Hematol. 2001;29:85-92.
81. Wen YJ, Ling M, Bailey-Wood R, et al. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res. 1998;4:957-962.
82. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer. 1999;83:215-222.
83. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood. 1999;93:2411-2419.
84. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2000;6:621-627.
85. Cull G, Durrant L, Stainer C, et al. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol. 1999;107:648-655.
86. Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol. 2000;108:805-816.
87. Yi Q, Desikan R, Barlogie B, et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol. 2002;117:297-305.
88. Curti A, Tosi P, Comoli P, et al. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br J Haematol. 2007; 139:415-424.
89. Bendandi M, Rodriguez-Calvillo M, Inoges S, et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma. 2006;47:29-37.
90. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997;3:558-561. (Pubitemid 27198656)
91. Gong J, Chen D, Kashiwaba M, et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA. 1998;95:6279-6283.
92. Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med. 2000;6:332-336.
93. Raje N, Hideshima T, Davies FE, et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004;125:343-352.
94. Hao S, Bi X, Xu S, et al. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Exp Oncol. 2004;26:300-306.
95. Walewska R, Teobald I, Dunnion D, et al. Preclinical development of hybrid cell vaccines for multiple myeloma. Eur J Haematol. 2007;78:11-20.
96. Stevenson FK, Link CJ Jr, Traynor A, et al. DNA vaccination against multiple myeloma. Semin Hematol. 1999;36:38-42.
97. Wendtner CM, Nolte A, Mangold E, et al. Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Ther. 1997;4:726-735.
98. Rice J, Elliott T, Buchan S, et al. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. J Immunol. 2001;167:1558-1565.
99. Trudel S, Li Z, Dodgson C, et al. Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma-a phase 1 study. Leukemia. 2001;15:846-854.
100. Angelucci E, Polchi P, Lucarelli G, et al. Allogeneic bone marrow transplantation for hematological malignancies following therapy with high doses of busulphan and cyclophosphamide. Haematologica. 1989;74:455-461.
101. Angelucci E, Baronciani D, Lucarelli G, et al. Long-term complete remission after allogeneic bone marrow transplantation in multiple myeloma. Bone Marrow Transplant. 1991;8:307-309.
102. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996;88:2787-2793.
103. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. [See comment.] N Engl J Med. 1991;325:1267-1273.
104. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotypespecific immunity from an actively immunised marrow donor. Lancet. 1995;345:1016-1020.
105. Neelapu SS, Munshi NC, Jagannath S, et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant. 2005;36:315-323.
106. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemiareactive cytotoxic T lymphocytes. Blood. 1999;94:1201-1208.
107. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
108. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA. 2004;101(suppl 2):14639-14645.
109. Lin MZ, Teitell MA, Schiller GJ. The evolution of antibodies into versatile tumor-targeting agents. Clin Cancer Res. 2005;11:129-138.
110. Owaidah TM, Aljurf MD. The evolving role of monoclonal antibodies and dendritic cell therapy in hematologic malignancies. Hematology. 2002;7: 265-272.
111. Reff ME, Hariharan K, Braslawsky G. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control. 2002;9:152-166.
112. Bjorkman PJ, Burmeister WP. Structures of two classes of MHC molecules elucidated: crucial differences and similarities. Curr Opin Struct Biol. 1994;4:852-856.
113. Strominger JL. Human histocompatibility proteins. Immunol Rev. 2002;185: 69-77.
114. Cooper EH, Plesner T. Beta-2-microglobulin review: its relevance in clinical oncology. Med Pediatr Oncol. 1980;8:323-334.
115. Shvidel L, Hofstein R, Berrebi A. Serum beta-2 microglobulin as a marker of B-cell activation in chronic lymphoid malignancies. Am J Hematol. 1996;53:148-149.
116. Molica S, Levato D, Cascavilla N, et al. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol. 1999;62: 117-122. (Pubitemid 29071271)
117. Bataille R, Durie BG, Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol. 1983;55:439-447.
118. Alexanian R, Barlogie B, Fritsche H. Beta 2 microglobulin in multiple myeloma. Am J Hematol. 1985;20:345-351.
119. Yang J, Qian J, Wezeman M, et al. Targeting beta(2)-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 2006;10:295-307.
120. Yang J, Cao Y, Hong S, et al. Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res. 2009;15:951-959.
121. Sekimoto E, Ozaki S, Ohshima T, et al. A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Res. 2007;67:1184-1192.
122. Nomura T, Huang WC, Seo S, et al. Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. J Urol. 2007;178:292-300.
123. Huang WC, Wu D, Xie Z, et al. beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res. 2006;66:9108-9116.
124. Yang J, Zhang X, Wang J, et al. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood. 2007;110:3028-3035.
125. Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14: 2775-2784.
126. Tai YT, Soydan E, Song W, et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009;113:4309-4318.
127. Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329-1337.
128. Tai YT, Catley LP, Mitsiades CS, et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004;64:2846-2852.
129. Tai YT, Li X, Tong X, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005;65:5898-5906.
130. Tai YT, Li XF, Catley L, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005;65: 11712-11720.
131. Anderson KC. New agents and approaches in the treatment of multiple myeloma. Clin Adv Hematol Oncol. 2003;1:151-152.